Short answer: GLP-1 medications (such as semaglutide) are among the fastest-growing costs in health plans, an estimated ~14% of 2026 drug spend, often more than $1,000 a month before rebates. Employers are deciding whether to cover them for weight loss and, if so, how to manage utilization.
GLP-1 drugs, first used for diabetes and now widely prescribed for weight loss, have become a major cost driver. Estimates put them around 14% of 2026 drug spend, with list prices over $1,000 per month before rebates and broad potential demand across the workforce.
The central employer decision is coverage scope: cover GLP-1s only for diabetes, or also for weight loss? Many plans that cover the weight-loss indication add guardrails: prior authorization, step therapy, BMI thresholds, and requirements to combine the drug with lifestyle programs, to control cost while preserving access for those who benefit most.
Sources
- KFF, Mercer, and SHRM 2026 pharmacy-cost analyses; Employee Benefits KB (Coverage Mechanics, pharmacy).
Content history
Originally published: June 16, 2026
Last reviewed: June 16, 2026